Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Elad Jacoby"'
Autor:
Carlos A. García-Prieto, Alvaro Urbano-Ispizua, Michal J. Besser, Orit Itzhaki, Concetta Quintarelli, Amilia Meir, Valentín Ortiz-Maldonado, Manuel Castro de Moura, Lorea Villanueva, Matilde Sinibaldi, Manel Juan, Gerardo Ferrer, Franco Locatelli, Europa Azucena González-Navarro, Francesca Del Bufalo, Elad Jacoby, Alberto Bueno-Costa, Veronica Davalos, Diana Bar, Marta Soler, Manel Esteller, Agustín F. Fernández, Mario F. Fraga, Abraham Avigdor, Julio Delgado, Rocío G. Urdinguio
Publikováno v:
Scopus
RUO. Repositorio Institucional de la Universidad de Oviedo
instname
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
RUO. Repositorio Institucional de la Universidad de Oviedo
instname
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Background: Chimeric antigen receptor (CAR) T cells directed against CD19 (CART19) are effective in B-cell malignancies, but little is known about the molecular factors predicting clinical outcome of CART19 therapy. The increasingly recognized releva
Autor:
Elad Jacoby, Katia Beider, Abraham Avigdor, Ivetta Danylesko, Arnon Nagler, Avichai Shimoni, Evgenia Rosenberg, Michal J. Besser, Olga Ostrovsky, Jacob Schachter, V. Voevoda-Dimenshtein
Publikováno v:
Hematological Oncology. 39
Publikováno v:
Immunological Reviews. 290:39-59
By increasing disease-free survival and offering the potential for long-term cure, chimeric antigen receptor (CAR) T-cell therapy has dramatically expanded therapeutic options among those with high-risk B-cell malignancies. As CAR T-cell utilization
Autor:
Katia Beider, Abraham Avigdor, Avichai Shimoni, Elad Jacoby, Arnon Nagler, Jacob Schachter, Michal J. Besser
Publikováno v:
Biology of Blood and Marrow Transplantation. 26:S314-S315
Chimeric antigen receptor (CAR) T cells have shown promising results in patients (pts) with B cell malignancies, yet approximately 60% of pts with diffuse large B cell lymphoma (DLBCL) will relapse. Therefore, future efforts are needed to improve the
Autor:
Michal J. Besser, Olga Ostrovsky, Jacob Schachter, Avichai Shimoni, Idit Wolf, Ania Hava Grushchenko-Polaq, Elad Jacoby, Katia Beider, Valeria Voevoda, Arnon Nagler
Publikováno v:
Blood. 134:3234-3234
Chimeric antigen receptor (CAR) T cells have shown promising results in patients (pts) with B cell malignancies, yet approximately 60% of pts with diffuse large B cell lymphoma (DLBCL) will relapse. Therefore, future efforts are needed to improve the
Autor:
Sang Minh Nguyen, Christopher D. Chien, Elad Jacoby, Haiying Qin, John F. Shern, Terry J. Fry, Kathryn M. Welp, Yinmeng Yang
Publikováno v:
Blood. 126:2524-2524
Resistance or relapse following adoptive immunotherapy can occur as a result of antigen loss. T cells armed with chimeric antigen receptors (CARs) targeting CD19 have shown remission rates of over 70% in early clinical trials, although reports of rel
Publikováno v:
Cancer Research. 75:4705-4705
Despite remarkable remission rates in relapsed and refractory acute lymphoblastic leukemia (ALL) following CD19 chimeric antigen receptor (CAR)-T cells or CD3-CD19 bispecific constructs, relapse of CD19 negative leukemic blasts occurs in approximatel